芬妥木單抗

化合物

芬妥木單抗INN:Figitumumab;開發代號:CP-751871)是一種針對胰島素樣生長因子1受體單株抗體[1]已被研究用於治療多種癌症,例如腎上腺皮質癌英語Adrenocortical carcinoma[2]非小細胞肺癌英語Non-small-cell lung cancer[3]

芬妥木單抗
單株抗體
種類完整抗體
目標IGF-1受體
臨床資料
ATC碼
  • 未分配
法律規範狀態
法律規範
  • 實驗性
識別資訊
CAS號943453-46-1  ☒N
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6462H9948N1736O2020S54
摩爾質量146,008.04 g·mol−1

這種藥物由輝瑞公司開發,但他們於2011年1月停止了該藥物的開發並停止了生產。[4]

臨床試驗

編輯

第一個III期試驗(針對非小細胞肺癌)因死亡人數過多而於2009年12月暫停,[5]但其他試驗仍在繼續。[6][7]

它將被納入I-SPY2乳腺癌試驗中。[8]

參考資料

編輯
  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab頁面存檔備份,存於互聯網檔案館), American Medical Association.
  2. ^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology. March 2010, 65 (4): 765–73. PMC 2875253 . PMID 19649631. doi:10.1007/s00280-009-1083-9. 
  3. ^ Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clinical Lung Cancer. July 2009, 10 (4): 273–80. PMID 19632947. doi:10.3816/CLC.2009.n.038. 
  4. ^ Cancer sufferer fears future without 'life-saver' drug. BBC News. July 2014 [2024-01-22]. (原始內容存檔於2015-09-25). 
  5. ^ Krauskopf L. Pfizer ends late-stage lung-cancer study. Reuters. 29 December 2009 [2024-01-22]. (原始內容存檔於2010-02-26). 
  6. ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
  7. ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
  8. ^ Breast cancer study aims to speed drugs, cooperation. Reuters. March 2010 [2024-01-22]. (原始內容存檔於2010-03-22).